trending Market Intelligence /marketintelligence/en/news-insights/trending/t0alawhizcvyblst1vjdpw2 content esgSubNav
In This List

Karyopharm Therapeutics elects director

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Karyopharm Therapeutics elects director

Newton, Mass.-based biotechnology company Karyopharm Therapeutics Inc. elected F. Carsten Thiel as a Class II director.

Thiel's term will expire at the company's 2021 annual meeting of stockholders.

Karyopharm's board increased the number of directors comprising the board to eight from seven and increased the number of Class II directors to two in connection with Thiel's appointment.